CTLA4 and cancer: Since the goal of cancer immune therapy is not to suppress the immune system, but to re-activate resting cells by modulation, which is currently successfully applied when using anti-CTLA4 antibodies, a more differentiated approach for the use of CA has to be advocated for anti-cancer treatment, specifically since it has a pronounced immune suppressive effect on T cells, including the effector T cell population.